What is the Market's View on Allogene Therapeutics Inc (ALLO) Stock's Price and Volume Trends Thursday?

The market has been neutral on Allogene Therapeutics Inc (ALLO) stock recently. ALLO gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Allogene Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ALLO!

See Full ALLO Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ALLO Stock Today?

Allogene Therapeutics Inc (ALLO) stock is trading at $15.91 as of 11:02 AM on Thursday, Dec 30, a rise of $0.56, or 3.65% from the previous closing price of $15.35. The stock has traded between $15.20 and $15.97 so far today. Volume today is below average. So far 276,958 shares have traded compared to average volume of 1,325,578 shares. To screen for more stocks like Allogene Therapeutics Inc click here.

More About Allogene Therapeutics Inc

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. Click Here to get the full Stock Report for Allogene Therapeutics Inc stock.